Equities

Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.86
  • Today's Change0.09 / 5.08%
  • Shares traded729.58k
  • 1 Year change-52.55%
  • Beta1.4919
Data delayed at least 15 minutes, as of Sep 18 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Verrica Pharmaceuticals Inc have a median target of 13.50, with a high estimate of 18.00 and a low estimate of 12.00. The median estimate represents a 629.73% increase from the last price of 1.85.
High873.0%18.00
Med629.7%13.50
Low548.6%12.00

Earnings history & estimates in USD

On Aug 14, 2024, Verrica Pharmaceuticals Inc reported 2nd quarter 2024 losses of -0.37 per share. This result exceeded the -0.43 consensus loss of the 5 analysts covering the company and under-performed last year's 2nd quarter results by 54.17%.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate-22.56%
Verrica Pharmaceuticals Inc reported annual 2023 losses of -1.48 per share on Feb 29, 2024.
Average growth rate-22.07%
More ▼

Revenue history & estimates in USD

Verrica Pharmaceuticals Inc. had 2nd quarter 2024 revenues of 5.18m. This bettered the 4.37m consensus of the 6 analysts covering the company. This was 13,891.89% above the prior year's 2nd quarter results.
Average growth rate+399.67%
Verrica Pharmaceuticals Inc. had revenues for the full year 2023 of 5.12m. This was 43.27% below the prior year's results.
Average growth rate-22.67%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.